Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Jade Biosciences, Inc. (NASDAQ:JBIO) has received a consensus rating of “Moderate Buy” from the ten research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $47.1250.

A number of analysts have commented on JBIO shares. Zacks Research upgraded Jade Biosciences from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 8th. UBS Group began coverage on shares of Jade Biosciences in a research note on Monday, June 15th. They issued a “buy” rating and a $45.00 target price for the company. Wedbush lifted their price target on Jade Biosciences from $34.00 to $45.00 and gave the company an “outperform” rating in a report on Tuesday, June 2nd. Weiss Ratings downgraded Jade Biosciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, June 16th. Finally, Guggenheim reissued a “buy” rating and set a $47.00 target price on shares of Jade Biosciences in a research report on Tuesday, June 2nd.

Jade Biosciences Trading Down 6.8%

JBIO stock traded down $1.53 on Friday, hitting $20.95. The company’s stock had a trading volume of 1,413,163 shares, compared to its average volume of 1,253,221. Jade Biosciences has a 1 year low of $6.67 and a 1 year high of $28.00. The stock has a market cap of $1.03 billion, a price-to-earnings ratio of -10.37 and a beta of 1.43. The firm has a 50 day moving average of $20.82 and a two-hundred day moving average of $17.70.

Jade Biosciences (NASDAQ:JBIO) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.05). As a group, equities analysts forecast that Jade Biosciences will post -2.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. RA Capital Management L.P. grew its position in shares of Jade Biosciences by 245.6% during the 4th quarter. RA Capital Management L.P. now owns 3,671,083 shares of the company’s stock valued at $56,645,000 after buying an additional 2,608,757 shares during the last quarter. Janus Henderson Group PLC bought a new stake in shares of Jade Biosciences during the first quarter valued at about $43,557,000. Baker BROS. Advisors LP acquired a new stake in shares of Jade Biosciences in the 4th quarter worth approximately $25,323,000. Remedium Capital Partners LLC acquired a new stake in Jade Biosciences in the fourth quarter worth approximately $24,345,000. Finally, Avidity Partners Management LP boosted its stake in Jade Biosciences by 24.3% during the fourth quarter. Avidity Partners Management LP now owns 1,400,708 shares of the company’s stock valued at $21,613,000 after buying an additional 273,522 shares in the last quarter.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.